Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.62 |
| ▸ | BLM | P54132 | 2/20 | 0.62 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.62 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.62 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | DRD1 | P21728 | 1/20 | 0.62 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.62 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.62 |
| ▸ | DRD3 | P35462 | 1/20 | 0.62 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.62 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.62 |
| ▸ | EYA2 | O00167 | 1/20 | 0.58 |
| ▸ | APP | P05067 | 1/20 | 0.58 |
| ▸ | ACE | P12821 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13060101 | 0.98 | TDP1 (0.58) | TDP1BLMPMP22KDM4ELMNA | |
| Edetic Acid SCHEMBL1077971 | 0.98 | TDP1 (0.61) | TDP1BLMPMP22KDM4ELMNA | |
| SCHEMBL22053950 | 0.98 | TDP1 (0.58) | TDP1BLMPMP22KDM4ELMNA | |
| SCHEMBL7587742 | 0.96 | TDP1 (0.54) | TDP1BLMPMP22KDM4ELMNA | |
| SCHEMBL111010 | 0.96 | TDP1 (0.56) | TDP1BLMPMP22KDM4ELMNA | |
| SCHEMBL11797447 | 0.94 | TDP1 (0.54) | TDP1BLMPMP22KDM4ELMNA | |
| SCHEMBL29223010 | 0.92 | TDP1 (0.54) | TDP1BLMPMP22KDM4ELMNA | |
| SCHEMBL27092853 | 0.92 | TDP1 (0.52) | TDP1BLMPMP22KDM4ELMNA | |
| Edetic Acid SCHEMBL4354138 | 0.91 | TDP1 (0.64) | TDP1BLMPMP22KDM4ELMNA | |
| SCHEMBL13354216 | 0.91 | TDP1 (0.52) | TDP1BLMPMP22KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1107979-B1 | LIPID MATRIX-ASSISTED CHEMICAL LIGATION AND SYNTHESIS OF MEMBRANE POLYPEPTIDES | GRYPHON THERAPEUTICS INC (US) | 2006-07-05 | — | — | EP | claimed |
| US-20030018169-A1 | Lipid matrix-assisted chemical ligation and synthesis of membrane polypeptides | AMYLIN PHARMACEUTICALS, INC. | 2003-01-23 | — | — | US | claimed |
| EP-1107979-A2 | LIPID MATRIX-ASSISTED CHEMICAL LIGATION AND SYNTHESIS OF MEMBRANE POLYPEPTIDES | Gryphon Sciences (US) | 2001-06-20 | — | — | EP | claimed |
| WO-2000012536-A2 | LIPID MATRIX-ASSISTED CHEMICAL LIGATION AND SYNTHESIS OF MEMBRANE POLYPEPTIDES | GRYPHON SCIENCES (US) | 2000-03-09 | — | — | WO | claimed |
| EP-3692032-B1 | CHEMICAL CONJUGATES OF EVANS BLUE DERIVATIVES AND THEIR USE AS RADIOTHERAPY AND IMAGING AGENTS | US HEALTH (US) | 2024-06-19 | — | — | EP | disclosed |
| CN-117917989-A | Use of a reversible metal electrodeposited electrolyte with pH-adjustable, dynamic glass element with high opacity and excellent rest stability, and electrolyte useful therefor | 代表内华达大学雷诺分校的内华达高等教育系统董事会 | 2024-04-23 | — | — | CN | disclosed |
| EP-4323615-A1 | DYNAMIC GLASS ELEMENT USING REVERSIBLE METAL ELECTRODEPOSITION ELECTROLYTES WITH TUNABLE PH WITH HIGH OPACITY AND EXCELLENT RESTING STABILITY AND ELECTROLYTES USEFUL THEREFORE | Board of Regents of the Nevada System of Higher Education, on Behalf of the University of Nevada, Reno (US) | 2024-02-21 | — | — | EP | disclosed |
| WO-2022221094-A1 | DYNAMIC GLASS ELEMENT USING REVERSIBLE METAL ELECTRODEPOSITION ELECTROLYTES WITH TUNABLE PH WITH HIGH OPACITY AND EXCELLENT RESTING STABILITY AND ELECTROLYTES USEFUL THEREFORE | THE BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION, ON BEHALF OF THE UNIVERSITY OF NEVADA, RENO (US) | 2022-10-20 | — | — | WO | disclosed |
| US-20220233726-A1 | NOVEL RADIOLABELLED COMPOUNDS FOR DIAGNOSIS OR TREATMENT OF PROSTATE-SPECIFIC MEMBRANE ANTIGEN-EXPRESSING CANCER | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2022-07-28 | — | — | US | disclosed |
| US-20220017495-A1 | CONJUGATES OF BIVALENT EVANS BLUE DYE DERIVATIVES AND METHODS OF USE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2022-01-20 | — | — | US | disclosed |
| EP-3918006-A2 | CONJUGATES OF BIVALENT EVANS BLUE DYE DERIVATIVES AND METHODS OF USE | The United States of America, as represented by The Secretary, Department of Health and Human Services (US) | 2021-12-08 | — | — | EP | disclosed |
| CN-113366064-A | Conjugates of divalent evans blue dye derivatives and methods of use | 美国政府健康及人类服务部 | 2021-09-07 | — | — | CN | disclosed |
| US-7282581-B2 | Oligonucleotide labeling reactants based on acyclonucleosides and conjugates derived thereof | WALLAC OY (FI) | 2007-10-16 | — | — | US | disclosed |
| US-7211440-B2 | Dissociative fluorescence enhancement assay | WALLAC OY (FI) | 2007-05-01 | — | — | US | disclosed |
| US-20070015284-A1 | Dissociative fluorescence enhancement assay | HEMMILA ILKKA | 2007-01-18 | — | — | US | disclosed |
| US-20030170907-A1 | Dissociative fluorescence enhancement assay | WALLAC OY (FI) | 2003-09-11 | — | — | US | disclosed |
| US-20030017504-A1 | Antibodies specific for poly(ethylene glycol) | SHEARWATER CORPORATION | 2003-01-23 | — | — | US | disclosed |
| WO-2002094853-A2 | ANTIBODIES SPECIFIC FOR POLY(ETHYLENE GLYCOL) | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2002-11-28 | — | — | WO | disclosed |
| US-4732887-A | RESIN IN VOIDS FOR CHROMATOGRAPHY | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1988-03-22 | — | — | US | disclosed |
| US-4599175-A | CHELATING RESIN | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1986-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030018169-A1 | Lipid matrix-assisted chemical ligation and synthesis of membrane polypeptides | PICALM, LPAR3, LDLR | TDP1 4810/4885BLM 1570/4885PMP22 347/4885 |
| US-20220017495-A1 | CONJUGATES OF BIVALENT EVANS BLUE DYE DERIVATIVES AND METHODS OF USE | NUCB2, RNPEP, MME | TDP1 3438/4885BLM 4633/4885PMP22 1363/4885 |
| US-20220233726-A1 | NOVEL RADIOLABELLED COMPOUNDS FOR DIAGNOSIS OR TREATMENT OF PROSTATE-SPECIFIC MEMBRANE ANTIGEN-EXPRESSING CANCER | KLK3, FOLH1, HRH3 | TDP1 3091/4885BLM 4487/4885PMP22 3104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.